Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06472674
Recruiting Observational

China Healthy Aging Cohort Study

NCT06472674 · tracked via the Priya Life Science China tracker
Sponsor
Xuanwu Hospital, Beijing
Phase
Observational
Started
2024-06-13
Last updated
2024-06-25

Condition(s) studied

Age ProblemDisabilityDementiaDeath

Investigational drug(s) / intervention(s)

No intervention

No intervention: No intervention

Study summary

This is a community-based prospective cohort study in China. The study has been initialized in 2024 and included older residents. The goal of this observational study is to explore the risk factors related to disability and dementia in the elderly Chinese community population, and develop a risk prediction model for disability and dementia.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Aged 60 years or older * Lived in the community for more than 1 year * Signed the informed consent form Exclusion Criteria: * Cannot complete the survey

Primary outcome measure(s)

  • The prevalence and incidence of functional disability using a population-based survey — An average of 1 to 2 years
    Functional disability was measured by Activities of Daily Living, cognitive function (Mini-Mental State Examination) and movement disorder（Short Physical Performance Battery) collected by questionnaires.The minimum value of the Activities of Daily Living is 0, and the maximum value is 100, the higher the score, the better the outcome.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.
  • The prevalence and incidence of mild cognitive impairment using a population-based survey — An average of 1 to 2 years
    Mild cognitive impairment was measured using Mini-Mental State Examination collected by questionnaire.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.
  • The prevalence and incidence of dementia using a population-based survey — An average of 1 to 2 years
    Dementia was determined by diagnosis of hospitalization or diagnosis of death or Clinical Dementia Rating scale. The minimum value of the Clinical Dementia Rating is 0, and the maximum value is 3, the higher the score, the worse the outcome.
  • The conversion rate of normal to mild cognitive impairment — An average of 1 to 2 years
    Percentage of enrolled population that convert from normal to mild cognitive impairment
  • The conversion rate of mild cognitive impairment to dementia — An average of 1 to 2 years
    Percentage of enrolled population that convert from mild cognitive impairment to dementia
  • The prevalence and incidence of movement disorder using a population-based survey — An average of 1 to 2 years
    Movement disorder was measured using Short Physical Performance Battery collected by questionnaire.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.

Trial sites (1)

FacilityCityRegionStatus
Xuanwu Hospital, Capital Medical University Beijing China Recruiting

More Xuanwu Hospital, Beijing trials in China

Study on the Incremental Predictive Value of Early Resting-State EEG Phenotypes for Functional Prognosis and Risk Stratification in Acute Ischemic Stroke Starting soon
Research, Development, and Application of Intelligent Diagnostic System for Orthostatic Hypotension Starting soon
Implantable Vagus Nerve Stimulation Modulation of Coeruleus-Norepinephrine Network for Mild-Moderate AD Patients Starting soon
Effect of WBT for CI With Depression Recruiting
Effect of Intranasal Negative Pressure Therapy on Cognitive Function in Patients With Mild Cognitive Impairment and Obstructive Sleep Apnea Starting soon

Other trials for the same condition

Fuzhou Aging Brain Health Initiative Recruiting
A Digitally-Enabled System for Precision Assessment and Intervention of Disability Risk in Older Adults Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Active, not recruiting
The Beijing Longitudinal Disability Survey in Community Elderly Recruiting
Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06472674 on ClinicalTrials.gov ↗ ← All trials in China